Corrigendum to “Furocoumarins affect hepatic cytochrome P450 and renal organic ion transporters in mice” [Toxicol. Lett. 209 (2012) 67–77] (Furocoumarins affect hepatic cytochrome P450 and renal organic ion transporters in mice (2012) 209(1) (67–77), (S0378427411016493), (10.1016/j.toxlet.2011.11.030));Furocoumarins affect hepatic cytochrome P450 and renal organic ion transporters in mice

Toxicology Letters

Volumn 209, Issue 1, 2012, Pages 67-77

  Wang, Xing ^a   Lou, Yu Jie ^a   Wang, Ming Xing ^a   Shi, Yun Wei ^a   Xu, Hong Xi ^b   Kong, Ling Dong ^a  

^a NANJING UNIVERSITY   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

CYP450; Furocoumarins; Liver and kidney toxicology; Organic ion transporters

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ANGELICIN; ASPARTATE AMINOTRANSFERASE; CARNITINE; CYTOCHROME P450; CYTOCHROME P450 2E1; CYTOCHROME P450 3A11; FUROCOUMARIN DERIVATIVE; GLUCOSE TRANSPORTER; ISOIMPERATORIN; METHOXSALEN; MULTIDRUG RESISTANCE PROTEIN 4; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 3; PENTOSALEN; PSORALEN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; FLUID INTAKE; FOOD INTAKE; LIVER TOXICITY; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WEIGHT REDUCTION;

MUS;

EID: 84155176897     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2021.08.011     Document Type: Erratum

References (69)

1. Aleksunes L.M., Augustine L.M., Scheffer G.L., Cherrington N.J., Manautou J.E. Renal xenobiotic transporters are differentially expressed in mice following cisplatin treatment. Toxicology 2008, 250:82-88.
2. Antolino-Lobo I., Meulenbelt J., Nijmeijer S.M., Maas-Bakker R.F., Meijerman I., van den Berg M., van Duursen M.B. 3,4-Methylenedioxymethamphetamine (MDMA) interacts with therapeutic drugs on CYP3A by inhibition of pregnane X receptor (PXR) activation and catalytic enzyme inhibition. Toxicol. Lett. 2011, 203:82-91.
3. Baumgart A., Schmidt M., Schmitz H.-J., Schrenk D. Natural furocoumarins as inducers and inhibitors of cytochrome P450 1A1 in rat hepatocytes. Biochem. Pharmacol. 2005, 69:657-667.
4. Bibert S., Hess S.K., Firsov D., Thorens B., Geering K., Horisberger J.D., Bonny O. Mouse GLUT9: evidences for a urate uniporter. Am. J. Physiol. Renal Physiol. 2009, 297:F612-F619.
5. Boadas-Vaello P., Jover E., Saldana-Ruiz S., Soler-Martin C., Chabbert C., Bayona J.M., Llorens J. Allylnitrile metabolism by CYP2E1 and other CYPs leads to distinct lethal and vestibulotoxic effects in the mouse. Toxicol. Sci. 2009, 107:461-472.
6. Burckhardt B.C., Burckhardt G. Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev. Physiol. Biochem. Pharmacol. 2003, 146:95-158.
7. Cai Y., Baer-Dubowska W., Ashwood-Smith M.J., Ceska O., Tachibana S., DiGiovanni J. Mechanism-based inactivation of hepatic ethoxyresorufin O-dealkylation activity by naturally occurring coumarins. Chem. Res. Toxicol. 1996, 9:729-736.
8. Carroll J.J., Coburn H., Douglass R., Babson A.L. A simplified alkaline phosphotungstate assay for uric acid in serum. Clin. Chem. 1971, 17:158-160.
9. Cederbaum A.I., Wu D., Mari M., Bai J. CYP2E1-dependent toxicity and oxidative stress in HepG2 cells. Free Radic. Biol. Med. 2001, 31:1539-1543.
10. Cerrutti J.A., Brandoni A., Quaglia N.B., Torres A.M. Sex differences in p-aminohippuric acid transport in rat kidney: role of membrane fluidity and expression of OAT1. Mol. Cell. Biochem. 2002, 233:175-179.
11. Cheung W.I., Tse M.L., Ngan T., Lin J., Lee W.K., Poon W.T., Mak T.W., Leung V.K.S., Chau T.N. Liver injury associated with the use of Fructus Psoraleae (Bol-gol-zhee or Bu-gu-zhi) and its related proprietary medicine. Clin. Toxicol. (Phila.) 2009, 47:683-685.
12. Deguchi T., Kusuhara H., Takadate A., Endou H., Otagiri M., Sugiyama Y. Characterization of uremic toxin transport by organic anion transporters in the kidney. Kidney Int. 2004, 65:162-174.
13. Dinour D., Gray N.K., Campbell S., Shu X., Sawyer L., Richardson W., Rechavi G., Amariglio N., Ganon L., Sela B.A., Bahat H., Goldman M., Weissgarten J., Millar M.R., Wright A.F., Holtzman E.J. Homozygous SLC2A9 mutations cause severe renal hypouricemia. J. Am. Soc. Nephrol. 2010, 21:64-72.
14. Enomoto A., Endou H. Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease. Clin. Exp. Nephrol. 2005, 9:195-205.
15. Enomoto A., Takeda M., Tojo A., Sekine T., Cha S.H., Khamdang S., Takayama F., Aoyama I., Nakamura S., Endou H., Niwa T. Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. J. Am. Soc. Nephrol. 2002, 13:1711-1720.
16. Feng L., Wang L., Jiang X. Pharmacokinetics, tissue distribution and excretion of coumarin components from Psoralea corylifolia L. in rats. Arch. Pharm. Res. 2010, 33:225-230.
17. Girennavar B., Jayaprakasha G.K., Patil B.S. Potent inhibition of human cytochrome P450 3A4, 2D6, and 2C9 isoenzymes by grapefruit juice and its furocoumarins. J. Food Sci. 2007, 72:C417-C421.
18. Glube N., Closs E., Langguth P. OCTN2-mediated carnitine uptake in a newly discovered human proximal tubule cell line (Caki-1). Mol. Pharm. 2007, 4:160-168.
19. Goldstein D.P., Carter D.M., Ljunggren B., Burkholder J. Minimal phototoxic doses and 8-MOP plasma levels in PUVA patients. J. Invest. Dermatol. 1982, 78:429-433.
20. Gorgus E., Lohr C., Raquet N., Guth S., Schrenk D. Limettin and furocoumarins in beverages containing citrus juices or extracts. Food Chem. Toxicol. 2010, 48:93-98.
21. Grover B., Buckley D., Buckley A.R., Cacini W. Reduced expression of organic cation transporters rOCT1 and rOCT2 in experimental diabetes. J. Pharmacol. Exp. Ther. 2004, 308:949-956.
22. Guengerich F.P. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J. 2006, 8:E101-E111.
23. Guo L.Q., Yamazoe Y. Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines. Acta Pharmacol. Sin. 2004, 25:129-136.
24. Habu Y., Yano I., Takeuchi A., Saito H., Okuda M., Fukatsu A., Inui K. Decreased activity of basolateral organic ion transports in hyperuricemic rat kidney: roles of organic ion transporters, rOAT1, rOAT3 and rOCT2. Biochem. Pharmacol. 2003, 66:1107-1114.
25. Hanna A.N., Sharma H.M., Kauffman E.M., Newman H.A. In vitro and in vivo inhibition of microsomal lipid peroxidation by MA-631. Pharmacol. Biochem. Behav. 1994, 48:505-510.
26. Hashimoto N., Sekiguchi H., Masunaka A., Saito K., Yamauchi H., Noda T., Han K.H., Fukushima M. Hepatic cytochrome P450 2E1 level rather than cecal condition contributes to induction of early stage of the alcoholic liver damage in rats. J. Health Sci. 2009, 55:356-362.
27. Hosoyamada M., Ichida K., Enomoto A., Hosoya T., Endou H. Function and localization of urate transporter 1 in mouse kidney. J. Am. Soc. Nephrol. 2004, 15:261-268.
28. Hosoyamada M., Sekine T., Kanai Y., Endou H. Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am. J. Physiol. 1999, 276:F122-F128.
29. Hu Q.H., Wang C., Li J.M., Zhang D.M., Kong L.D. Allopurinol, rutin, and quercetin attenuate hyperuricemia and renal dysfunction in rats induced by fructose intake: renal organic ion transporter involvement. Am. J. Physiol. Renal Physiol. 2009, 297:F1080-F1091.
30. Imaoka T., Kusuhara H., Adachi-Akahane S., Hasegawa M., Morita N., Endou H., Sugiyama Y. The renal-specific transporter mediates facilitative transport of organic anions at the brush border membrane of mouse renal tubules. J. Am. Soc. Nephrol. 2004, 15:2012-2022.
31. Kakehi M., Koyabu N., Nakamura T., Uchiumi T., Kuwano M., Ohtani H., Sawada Y. Functional characterization of mouse cation transporter mOCT2 compared with mOCT1. Biochem. Biophys. Res. Commun. 2002, 296:644-650.
32. Khor C.C., Davila S., Shimizu C., Sheng S., Matsubara T., Suzuki Y., Newburger J.W., Baker A., Burgner D., Breunis W., Kuijpers T., Wright V.J., Levin M., Hibberd M.L., Burns J.C. Genome-wide linkage and association mapping identify susceptibility alleles in ABCC4 for Kawasaki disease. J. Med. Genet. 2011, 48:467-472.
33. Kikuchi R., Kusuhara H., Hattori N., Shiota K., Kim I., Gonzalez F.J., Sugiyama Y. Regulation of the expression of human organic anion transporter 3 by hepatocyte nuclear factor 1 alpha/beta and DNA methylation. Mol. Pharmacol. 2006, 70:887-896.
34. Kim H.J., Chang E.J., Cho S.H., Chung S.K., Park H.D., Choi S.W. Antioxidative activity of resveratrol and its derivatives isolated from seeds of Paeonia lactiflora. Biosci. Biotechnol. Biochem. 2002, 66:1990-1993.
35. Kim S.G., Chung H.C., Cho J.Y. Molecular mechanism for alkyl sulfide-modulated carbon tetrachloride-induced hepatotoxicity: the role of cytochrome P450 2E1, P450 2B and glutathione S-transferase expression. J. Pharmacol. Exp. Ther. 1996, 277:1058-1066.
36. Kimura T., But P.P.H., Guo J.X., Sung C.K. International collation of traditional and folk medicine: Part 1 1996, World Scientific, Singapore, pp. 117-118.
37. Kleiner H.E., Vulimiri S.V., Miller L., Johnson W.H., Whitman C.P., DiGiovanni J. Oral administration of naturally occurring coumarins leads to altered phase I and II enzyme activities and reduced DNA adduct formation by polycyclic aromatic hydrocarbons in various tissues of SENCAR mice. Carcinogenesis 2001, 22:73-82.
38. Kleiner H.E., Xia X., Sonoda J., Zhang J., Pontius E., Abey J., Evans R.M., Moore D.D., DiGiovanni J. Effects of naturally occurring coumarins on hepatic drug-metabolizing enzymes in mice. Toxicol. Appl. Pharmacol. 2008, 232:337-350.
39. Koenigs L.L., Trager W.F. Mechanism-based inactivation of cytochrome P450 2B1 by 8-methoxypsoralen and several other furanocoumarins. Biochemistry 1998, 37:13184-13193.
40. Koepsell H. Polyspecific organic cation transporters: their functions and interactions with drugs. Trends Pharmacol. Sci. 2004, 25:375-381.
41. Kummer O., Hammann F., Moser C., Schaller O., Drewe J., Krahenbuhl S. Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Eur. J. Clin. Pharmacol. 2011, 67:63-71.
42. Lamba J.K., Adachi M., Sun D., Tammur J., Schuetz E.G., Allikmets R., Schuetz J.D. Nonsense mediated decay downregulates conserved alternatively spliced ABCC4 transcripts bearing nonsense codons. Hum. Mol. Genet. 2003, 12:99-109.
43. Li S., Chen Y., Zhang S., More S.S., Huang X., Giacomini K.M. Role of organic cation transporter 1, OCT1 in the pharmacokinetics and toxicity of cis-diammine(pyridine)chloroplatinum(II) and oxaliplatin in mice. Pharm. Res. 2011, 28:610-625.
44. Lou Y., Li J., Lu Y., Wang X., Jiao R., Wang S., Kong L. Aristolochic acid-induced destruction of organic ion transporters and fatty acid metabolic disorder in the kidney of rats. Toxicol. Lett. 2011, 201:72-79.
45. Lu K., Nishimori H., Nakamura Y., Shima K., Kuwajima M. A missense mutation of mouse OCTN2, a sodium-dependent carnitine cotransporter, in the juvenile visceral steatosis mouse. Biochem. Biophys. Res. Commun. 1998, 252:590-594.
46. Luszczki J.J., Glowniak K., Czuczwar S.J. Imperatorin enhances the protective activity of conventional antiepileptic drugs against maximal electroshock-induced seizures in mice. Eur. J. Pharmacol. 2007, 574:133-139.
47. Millonig G., Wang Y., Homann N., Bernhardt F., Qin H., Mueller S., Bartsch H., Seitz H.K. Ethanol-mediated carcinogenesis in the human esophagus implicates CYP2E1 induction and the generation of carcinogenic DNA-lesions. Int. J. Cancer 2011, 128:533-540.
48. Mutsaers H.A.M., van den Heuvel L.P., Ringens L.H.J., Dankers A.C.A., Russel F.G.M., Wetzels J.F.M., Hoenderop J.G., Masereeuw R. Uremic toxins inhibit transport by breast cancer resistance protein and multidrug resistance protein 4 at clinically relevant concentrations. PLoS One 2011, 6:e18438.
49. Nam S.W., Baek J.T., Lee D.S., Kang S.B., Ahn B.M., Chung K.W. A case of acute cholestatic hepatitis associated with the seeds of Psoralea corylifolia (Boh-Gol-Zhee). Clin. Toxicol. (Phila.) 2005, 43:589-591.
50. Neuvonen P.J., Kantola T., Kivisto K.T. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin. Pharmacol. Ther. 1998, 63:332-341.
51. Nowicki M.T., Aleksunes L.M., Sawant S.P., Dnyanmote A.V., Mehendale H.M., Manautou J.E. Renal and hepatic transporter expression in type 2 diabetic rats. Drug Metab. Lett. 2008, 2:11-17.
52. Preitner F., Bonny O., Laverriere A., Rotman S., Firsov D., Da Costa A., Metref S., Thorens B. Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:15501-15506.
53. Rakhit A., Pantze M.P., Fettner S., Jones H.M., Charoin J.-E., Riek M., Lum B.L., Hamilton M. The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition. Eur. J. Clin. Pharmacol. 2008, 64:31-41.
54. Sabers A. Pharmacokinetic interactions between contraceptives and antiepileptic drugs. Seizure 2008, 17:141-144.
55. Saito H. Pathophysiological regulation of renal Slc22a organic ion transporters in acute kidney injury: pharmacological and toxicological implications. Pharmacol. Ther. 2010, 125:79-91.
56. Schoonderwoerd S.A., Beijersbergen van Henegouwen G.M., Persons C.C., Caffieri S., Dall'Acqua F. Photobinding of 8-methoxypsoralen, 4,6,4'-trimethylangelicin and chlorpromazine to Wistar rat epidermal biomacromolecules in vivo. J. Photochem. Photobiol. B 1991, 10:257-268.
57. Stark K., Reinhard W., Neureuther K., Wiedmann S., Sedlacek K., Baessler A., Fischer M., Weber S., Kaess B., Erdmann J., Schunkert H., Hengstenberg C. Association of common polymorphisms in GLUT9 gene with gout but not with coronary artery disease in a large case-control study. PLoS One 2008, 3:e1948.
58. Struwe M., Greulich K.-O., Junker U., Jean C., Zimmer D., Suter W., Plappert-Helbig U. Detection of photogenotoxicity in skin and eye in rat with the photo comet assay. Photochem. Photobiol. Sci. 2008, 7:240-249.
59. Sweet D.H. Organic anion transporter (Slc22a) family members as mediators of toxicity. Toxicol. Appl. Pharmacol. 2005, 204:198-215.
60. Tamai I., Yabuuchi H., Nezu J., Sai Y., Oku A., Shimane M., Tsuji A. Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. FEBS Lett. 1997, 419:107-111.
61. Terada T., Inui K. Gene expression and regulation of drug transporters in the intestine and kidney. Biochem. Pharmacol. 2007, 73:440-449.
62. Wang C.-P., Wang X., Zhang X., Shi Y.-W., Liu L., Kong L.-D. Morin improves urate excretion and kidney function through regulation of renal organic ion transporters in hyperuricemic mice. J. Pharm. Pharm. Sci. 2010, 13:411-427.
63. Wu D., Cederbaum A.I. Ethanol and arachidonic acid produce toxicity in hepatocytes from pyrazole-treated rats with high levels of CYP2E1. Mol. Cell. Biochem. 2000, 204:157-167.
64. Wu W., Dnyanmote A.V., Nigam S.K. Remote communication through solute carriers and ATP binding cassette drug transporter pathways: an update on the remote sensing and signaling hypothesis. Mol. Pharmacol. 2011, 79:795-805.
65. Xu Q., Pan Y., Yi L.T., Li Y.C., Mo S.F., Jiang F.X., Qiao C.F., Xu H.X., Lu X.B., Kong L.D., Kung H.F. Antidepressant-like effects of psoralen isolated from the seeds of Psoralea corylifolia in the mouse forced swimming test. Biol. Pharm. Bull. 2008, 31:1109-1114.
66. Yokoo K., Murakami R., Matsuzaki T., Yoshitome K., Hamada A., Saito H. Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats. Clin. Exp. Nephrol. 2009, 13:578-584.
67. Zair Z.M., Eloranta J.J., Stieger B., Kullak-Ublick G.A. Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney. Pharmacogenomics 2008, 9:597-624.
68. Zhou S.-F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr. Drug Metab. 2008, 9:310-322.
69. Zlender V., Breljak D., Ljubojevic M., Flajs D., Balen D., Brzica H., Domijan A.-M., Peraica M., Fuchs R., Anzai N., Sabolic I. Low doses of ochratoxin A upregulate the protein expression of organic anion transporters Oat1, Oat2, Oat3 and Oat5 in rat kidney cortex. Toxicol. Appl. Pharmacol. 2009, 239:284-296.